StocksMedium•5 October 2026•
1 min read
Genmab Shares Rise on Positive Ovarian Cancer Drug Trial Results
Key Facts
1Genmab's Rina-S drug showed a 45.9% response rate in Phase 2 trials for ovarian cancer treatment.
Genmab shares experienced a price jump following the release of positive clinical trial data for its ovarian cancer drug, Rina-S. Investing.com reported that the Phase 2 trials demonstrated a 45.9% response rate, providing significant clinical validation for the drug's efficacy.
The stock saw bullish momentum driven by the durable response data and the clinical progress of the treatment candidate. This appreciation reflects positive sentiment within the oncology segment.